Wyden seeking list of drugs based on NIH research

Sen. Ron Wyden (D-Ore.) sent a JAK-3 that he said helped lead to the development of rheumatoid arthritis drug Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE). According to Wyden, "taxpayer-funded research was foundational" to the development of the oral pan-Janus kinase (JAK) inhibitor, though he acknowledged Pfizer funded all drug discovery, preclinical and clinical development expenses. In response, the pharma said it has invested over $1 billion over the past 20 years for the discovery, development and commercialization of Xeljanz. Pfizer also said the CRADA did not yield any compounds or patentable IP.

Wyden made similar requests in the early 90s seeking to regulate prices on drugs developed with the aid of federal resources (see BioCentury, Feb. 1, 1993). ...